福華化學競得尚緯股份2600萬股,占上市公司總股本的4.18%
據公開消息,4月14日福華化學通過阿里司法拍賣平台,以約1.22億元競得尚緯股份(603333.SH)2600萬股股票,占上市公司總股本的4.18%。此輪拍賣的股票過户後,福華化學共持有尚緯股份19.56%的股份。投資者對於福華化學後續將如何影響尚緯股份的發展戰略、業務佈局等方面充滿期待。尚緯股份是電線電纜行業的知名企業,福華化學在化工領域實力強勁,二者後續是否會在產業協同、資源整合等方面開展深度合作,成為市場關注焦點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.